RAN Translation in Neurodegeneration

RAN Translation in Neurodegeneration

Introduction

Ran Translation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

RAN Translation in Neurodegeneration

Introduction

Ran Translation In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Repeat-associated non-AUG (RAN) translation is an unconventional form of protein synthesis that initiates within expanded microsatellite repeat sequences without requiring a canonical AUG start codon. Discovered in 2011 by Laura Ranum and colleagues at the University of Florida, RAN translation represents a paradigm shift in understanding how [trinucleotide-repeat-expansion](/mechanisms/trinucleotide-repeat-expansion) cause neuronal toxicity. Unlike classical translation, which requires scanning from a 5' cap to the first AUG codon, RAN translation can initiate in all three reading frames and from both sense and antisense repeat-containing transcripts, producing multiple toxic homopolymeric or dipeptide repeat (DPR) proteins. RAN translation has been implicated in the pathogenesis of [als](/diseases/amyotrophic-lateral-sclerosis)/[ftd](/diseases/frontotemporal-dementia) , [huntington-pathway](/mechanisms/huntington-pathway), spinocerebellar ataxias, [myotonic-dystrophy](/diseases/myotonic-dystrophy), and [friedreichs-ataxia](/diseases/friedreichs-ataxia). [@cleary2017]

Discovery and Mechanism

Initial Discovery

RAN translation was first described in Spinocerebellar Ataxia type 8 (SCA8) and myotonic dystrophy type 1 (DM1). Zu et al. (2011) demonstrated that expanded CAG repeats could be translated in all three reading frames (producing polyglutamine, polyalanine, and polyserine) without an AUG start codon, both in vitro and in vivo [@zu2011]. This finding challenged the long-held assumption that CAG repeat disorders caused toxicity solely through the canonical polyglutamine-containing protein product. [@green2017]

Mechanistic Features

Key characteristics of RAN translation include: [@banezcoronel2015]

Role of RNA Secondary Structure

Expanded repeats form stable secondary structures that are critical for RAN translation: [@mori2013]

• CAG/CUG repeats: Form hairpin structures with A-A or U-U mismatches
• CGG/CCG repeats: Form stable hairpins with G-G mismatches
• GGGGCC/CCCCGG repeats: Form G-quadruplexes (sense) and i-motifs (antisense)

RAN Translation in C9orf72-ALS/FTD

The C9orf72 Repeat Expansion

The hexanucleotide repeat expansion (GGGGCC)n in the [c9orf72](/genes/c9orf72) gene is the most common known genetic cause of both [als](/diseases/amyotrophic-lateral-sclerosis) and [ftd](/diseases/frontotemporal-dementia), accounting for approximately 40% of familial ALS and 25% of familial FTD cases. Healthy individuals carry 2–25 repeats, while affected patients typically harbor hundreds to thousands of repeats. [@haeusler2016]

Dipeptide Repeat Proteins

RAN translation of the [c9orf72](/genes/c9orf72) expansion produces five distinct dipeptide repeat (DPR) proteins from sense and antisense transcripts:

| DPR | Transcript | Reading Frame | Charge | Localization | Toxicity |
|-----|-----------|---------------|--------|-------------|----------|
| Poly-GA (glycine-alanine) | Sense | Frame 1 | Neutral | Cytoplasmic inclusions | High |
| Poly-GP (glycine-proline) | Sense/Antisense | Frame 2 | Neutral | Cytoplasmic | Moderate |
| Poly-GR (glycine-arginine) | Sense | Frame 3 | Positive | Nuclear/nucleolar | Very high |
| Poly-PA (proline-alanine) | Antisense | Frame 1 | Neutral | Cytoplasmic | Low |
| Poly-PR (proline-arginine) | Antisense | Frame 2 | Positive | Nuclear/nucleolar | Very high |

DPR Toxicity Mechanisms

Poly-GA

Poly-GA is the most abundantly produced DPR and forms p62-positive cytoplasmic inclusions throughout the CNS. It contributes to toxicity through:

• Sequestration of [ubiquitin-proteasome-system](/mechanisms/ubiquitin-proteasome-system) components, impairing proteostasis
• Induction of [tdp-43](/proteins/tdp-43) cleavage and mislocalization, linking RAN translation to [tdp-43](/proteins/tdp-43) proteinopathy
• Activation of [caspase-3](/proteins/caspase-3)-dependent [apoptosis](/mechanisms/apoptosis) in a dose-dependent manner
• Inhibition of [autophagy]/mechanisms/autophagy) through sequestration of HR23 proteins (May et al., 2014 [@freibaum2012]; Zhang et al., 2016 [@haeusler2016])

Poly-GR and Poly-PR (Arginine-Rich DPRs)

The arginine-containing DPRs are the most toxic and primarily localize to the nucleus and nucleolus:

• Ribosomal impairment: Poly-GR binds to 60S ribosomal subunits and impairs translation elongation, causing a global translational stall and activating the ribotoxic stress response via the ZAKα-p38 signaling pathway (Moens et al., 2019).
• Nucleocytoplasmic transport disruption: Arginine-rich DPRs interact with nuclear pore complex components and importins, disrupting nucleocytoplasmic transport. The nuclear import receptor Kapβ2/Transportin-1 modulates poly-GR neurotoxicity (Nanaura et al., 2024).
• Phase separation disruption: Poly-GR and poly-PR undergo [liquid-liquid-phase-separation](/mechanisms/liquid-liquid-phase-separation) and disrupt the dynamics of membraneless organelles, including [stress-granules](/mechanisms/stress-granules), nucleoli, and nuclear speckles (Lee et al., 2016).
• DNA damage: Arginine-rich DPRs impair DNA repair by disrupting ATM signaling and sequestering DNA damage response factors.

Regulatory Mechanisms

Recent research has identified key regulators of [c9orf72](/genes/c9orf72) RAN translation:

• MARK2 (Microtubule Affinity-Regulating Kinase 2): Acts as an eIF2α kinase that enhances RAN translation under proteotoxic stress. MARK2 inhibition reduces DPR production in patient-derived [neurons](/entities/neurons) (Cheng et al., 2025).
• Cryptic transcriptional initiation: Intronic transcriptional start sites within the [c9orf72](/genes/c9orf72) locus generate endogenous mRNA templates that efficiently drive RAN translation, providing a mechanism for DPR production even from intron-retained transcripts (Almeida et al., 2025).

RAN Translation in Huntington's Disease

CAG Repeat RAN Products

In [huntington-pathway](/mechanisms/huntington-pathway), the expanded CAG repeat in the [huntingtin](/proteins/huntingtin) gene] undergoes RAN translation in addition to canonical translation of the polyglutamine tract:

• Polyalanine (polyA): Produced from the GCA reading frame
• Polyserine (polyS): Produced from the AGC reading frame
• Polyglutamine (polyQ): Canonical and RAN-derived

CUG Repeat Products

Antisense transcription across the CAG repeat produces CUG repeat RNAs that undergo RAN translation, generating polyleucine, polycysteine, and polyalanine peptides. These antisense RAN products accumulate in HD striatum, the brain region most vulnerable to degeneration.

RAN Translation in Spinocerebellar Ataxias

SCA8

SCA8 was the first disorder in which RAN translation was demonstrated. The CTG·CAG repeat expansion produces:

• Sense strand: polyglutamine (canonical ATXN8 protein) and RAN-translated polyalanine and polyserine
• Antisense strand: polyleucine, polyalanine, and polycysteine

SCA31

The TGGAA repeat expansion in SCA31 undergoes RAN translation producing poly(WNGME) pentapeptide repeat proteins. These pentapeptide products form nuclear inclusions in cerebellar Purkinje cells.

Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS)

In [fxtas](/diseases/fxtas), the CGG repeat expansion in the FMR1 5' UTR undergoes RAN translation producing:

• FMRpolyG (polyglycine): The predominant RAN product, found in ubiquitin-positive intranuclear inclusions in FXTAS patient brains
• FMRpolyA (polyalanine): Less abundant, detected in neuronal inclusions

RAN Translation in Myotonic Dystrophy

[myotonic-dystrophy](/diseases/myotonic-dystrophy) types 1 (DM1, CTG expansion in DMPK) and 2 (DM2, CCTG expansion in CNBP) both show evidence of RAN translation. In DM1, antisense CAG repeat transcripts produce polyglutamine proteins that accumulate in affected tissues. The expanded CUG RNA also sequesters MBNL1 splicing factor, compounding toxicity from both RNA gain-of-function and RAN-derived protein products.

Therapeutic Strategies

Targeting RAN Translation Directly

• Integrated stress response (ISR) modulation: Since eIF2α phosphorylation enhances RAN translation, ISR inhibitors such as ISRIB may reduce DPR production. However, the ISR also mediates beneficial adaptive responses, requiring careful therapeutic calibration.
• [mtor-neurodegeneration](/mechanisms/mtor-neurodegeneration) pathway modulation: [mtor-neurodegeneration](/mechanisms/mtor-neurodegeneration) signaling influences RAN translation efficiency; rapamycin and rapalogs may reduce DPR production.
• Metformin: Has been shown to reduce RAN translation of CGG repeats in FXTAS models, possibly through AMPK-mediated signaling.

Reducing Repeat-Containing RNA

• [antisense-oligonucleotide-therapy](/therapeutics/antisense-oligonucleotide-therapy): ASOs targeting the [c9orf72](/genes/c9orf72) sense transcript reduce both RNA foci and DPR production. [tofersen](/therapeutics/tofersen)-like approaches for [c9orf72](/genes/c9orf72) are in clinical development.
• [crispr-gene-editing](/therapeutics/crispr-gene-editing): Gene editing to excise the repeat expansion or modulate transcription from the expanded locus.
• Small molecules targeting repeat RNA structure: Compounds that bind the G-quadruplex or hairpin structures of expanded repeats can inhibit RAN translation initiation.

Targeting DPR Toxicity

• Anti-DPR antibodies: Passive immunization with antibodies against poly-GA or poly-GP has shown efficacy in [c9orf72](/genes/c9orf72) mouse models, reducing DPR burden and improving behavioral outcomes.
• PKR pathway inhibition: Inhibiting the protein kinase R (PKR) pathway decreases RAN protein levels and improves disease phenotypes in preclinical models.

Biomarker Applications

DPR proteins, particularly poly-GP, are detectable in [csf](/diagnostics/csf-biomarkers) of [c9orf72](/genes/c9orf72) expansion carriers and serve as pharmacodynamic biomarkers in clinical trials. Reduction of CSF poly-GP levels has been used as a primary endpoint for ASO therapies targeting [c9orf72](/genes/c9orf72) repeat RNA.

Clinical Translation and Patient Impact

The translation of RAN translation research into clinical practice represents a rapidly evolving frontier in neurodegenerative disease therapeutics. As our understanding of how repeat-associated non-AUG translation contributes to disease pathogenesis has deepened, several therapeutic approaches have advanced toward clinical application, with measurable impacts on patient care and disease monitoring.

Clinical Trials and Therapeutic Pipeline

Several clinical programs have emerged that directly target RAN translation mechanisms or their downstream effects:

Antisense Oligonucleotide (ASO) Therapies: The most advanced RAN translation-targeted approach involves ASOs designed to reduce C9orf72 repeat-containing RNA. Tofersen, an ASO targeting the SOD1 gene in [ALS](/diseases/amyotrophic-lateral-sclerosis), demonstrated the regulatory approval pathway for this class of therapeutics. Similar ASO approaches for C9orf72-associated disease have shown promise in preclinical studies, with CSF poly-GP reduction serving as a pharmacodynamic biomarker [@zu2011]. Clinical trials evaluating C9orf72-targeting ASOs are actively recruiting, representing the first direct tests of RAN translation inhibition in human patients.

Small Molecule Inhibitors: Several pharmaceutical companies are developing small molecules that target RAN translation initiation. These include compounds that:

• Bind to G-quadruplex structures in repeat RNA
• Modulate integrated stress response signaling
• Inhibit eIF2α phosphorylation to reduce RAN translation efficiency

Biomarker-Driven Patient Selection

The identification of DPR proteins in CSF has enabled biomarker-driven patient selection for clinical trials. Poly-GP levels in CSF correlate with disease progression and therapeutic target engagement, allowing:

• Patient stratification: Selecting patients with detectable DPR levels for enrollment
• Dose-finding: Using biomarker changes to optimize dosing regimens
• Early efficacy signals: Detecting biological effects before clinical endpoints

Patient Impact and Quality of Life

The clinical translation of RAN translation research has several important implications for patients and families:

Disease-Modifying Potential: Unlike symptomatic treatments, RAN translation-targeted therapies aim to modify the underlying disease process by reducing toxic DPR production. This represents a paradigm shift from supportive care toward disease modification.

Personalized Medicine: The identification of specific repeat expansions (C9orf72, ATXN2, HTT) allows for genotype-specific treatment approaches. Patients can be screened for repeat expansions and enrolled in targeted therapy programs.

Family Planning: Genetic testing for repeat expansions enables at-risk individuals and families to make informed decisions about family planning and early intervention strategies.

Ongoing Clinical Trials and Recent Results

Recent clinical trials have begun evaluating RAN translation-targeted therapies in human patients. The WVE-004 program (Wave Life Sciences) specifically targets C9orf72 repeat-containing RNA and has completed Phase 1/2 testing in ALS and FTD patients. Initial results demonstrated dose-dependent reduction in cerebrospinal fluid poly-GP levels, providing evidence of target engagement and RAN translation inhibition in patients [@wve2024]. Similarly, the BIIB078 program (Biogen) evaluated a C9orf72-targeting ASO, though results showed limited clinical benefit despite biomarker modulation [@biib2024].

Several factors may explain the modest clinical outcomes observed in initial RAN translation-targeted trials:

Disease Stage at Treatment: Most enrolled patients had moderate to advanced disease, with significant neuronal loss already present.RAN translation inhibition may be most effective in earlier disease stages or pre-symptomatic carriers.

Biomarker Validation: While poly-GP reduction demonstrates target engagement, the relationship between CSF DPR levels and actual neuronal DPR burden remains incompletely characterized.

Off-Target Effects: ASO delivery to the central nervous system is not uniform, and therapeutic effects may vary across brain regions.

Therapeutic Implications and Development Pipeline

The RAN translation mechanism offers several distinct therapeutic targets that are actively being pursued:

RNA-Targeting Approaches: Beyond ASOs, alternative RNA-targeting modalities are in development:

• Splice-switching oligonucleotides: Designed to modify RNA splicing to exclude expanded repeat regions
• Small interfering RNA (siRNA): Vector-delivered gene silencing approaches
• RNA-binding protein modulators: Compounds that alter RBP function to reduce RAN translation efficiency

• Autophagy enhancers: Promote clearance of aggregated DPR proteins
• Proteasome modulators: Enhance protein quality control mechanisms
• Aggregate-busting compounds: Small molecules designed to disassemble DPR aggregates

• eIF2α phosphatase inhibitors: Reduce eIF2α phosphorylation to decrease RAN translation
• ISR modulators: Target PERK, GCN2, and PKR pathways that regulate RAN translation

Biomarker Connections and Diagnostic Development

The development of biomarkers for RAN translation disorders has advanced significantly:

Cerebrospinal Fluid Biomarkers: Multiple DPR species can be detected in CSF:

• Poly-GP: Most extensively validated, correlates with disease burden
• Poly-GA: Highly abundant, technically easier to detect
• Poly-PR/GP: Arginine-containing DPRs more difficult to measure

• Neurofilament light chain (NfL): Non-specific marker of neuroaxonal injury
• Tau and p-tau: Disease progression markers
• Emerging DPR assays: Promise for less invasive monitoring

• PET tracers: Target to visualize DPR deposition in vivo
• MR spectroscopy: Metabolic changes associated with RAN translation
• Diffusion tensor imaging: White matter integrity as disease biomarker

Regulatory Considerations and Approval Pathways

The regulatory landscape for RAN translation-targeted therapies is evolving:

Breakthrough Therapy Designation: Given the unmet need in ALS and FTD, several programs have received breakthrough therapy designation, enabling:

• Accelerated approval pathways
• Intensive FDA guidance
• Rolling review of clinical data

• Platform trials for neurodegenerative diseases
• Adaptive designs allowing mid-study modifications
• Master protocols enabling efficient evaluation of multiple agents

• Patient-reported outcomes in clinical trials
• Natural history studies to inform trial design
• Clinical outcome assessments validated for neurodegenerative diseases

Challenges and Future Directions

Several challenges remain in translating RAN translation research to clinical practice:

Blood-Brain Barrier Delivery: ASOs and large molecules require intrathecal delivery, which is invasive. Alternative delivery approaches, including viral vector-mediated gene therapy and novel nanoparticle carriers, are under development.

Timing of Intervention: Clinical trials may need to target pre-symptomatic or early-symptomatic patients when neuronal loss is less advanced. This requires improved diagnostic biomarkers and earlier detection methods.

Combination Therapies: Given the complex pathophysiology of neurodegeneration, RAN translation inhibition may need to be combined with other disease-modifying approaches targeting complementary mechanisms.

Long-Term Safety: The long-term effects of chronic RAN translation modulation remain unknown. The integrated stress response plays important physiological roles, requiring careful safety monitoring.

Despite these challenges, the translation of RAN translation research from basic discovery to clinical application represents one of the most promising frontiers in neurodegenerative disease therapeutics. The availability of biomarker tools, clear mechanistic targets, and advancing clinical trial infrastructure provide reason for optimism in developing disease-modifying treatments for patients with repeat-expansion disorders.

References

See Also

• [Neurodegeneration](/diseases/neurodegeneration)
• [trinucleotide-repeat-expansion](/mechanisms/trinucleotide-repeat-expansion)
• [als](/diseases/amyotrophic-lateral-sclerosis)
• [ftd](/diseases/frontotemporal-dementia)
• [huntington-pathway](/mechanisms/huntington-pathway)
• [myotonic-dystrophy](/diseases/myotonic-dystrophy)
• [friedreichs-ataxia](/diseases/friedreichs-ataxia)
• [c9orf72](/genes/c9orf72)
• [ubiquitin-proteasome-system](/mechanisms/ubiquitin-proteasome-system)
• [tdp-43](/proteins/tdp-43)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

Therapeutic Approaches

Targeting RAN translation has emerged as a promising therapeutic strategy for repeat-expansion disorders. Several approaches are being investigated to suppress or modulate RAN translation. Antisense oligonucleotides (ASOs) designed to bind repeat-containing RNAs can reduce RAN translation by blocking ribosomal scanning or promoting RNase H-mediated degradation. Small molecule inhibitors targeting translation initiation factors or ribosome recruitment are also under development. Gene therapy approaches using CRISPR-Cas systems aim to correct the repeat expansion or allele-specifically silence mutant transcripts. Clinical trials for C9orf72-associated ALS/FTD are evaluating ASOs such as WVE-004 and BIIB078, which target the expanded repeat RNA. These therapeutic strategies hold promise for modifying disease progression in multiple repeat-expansion disorders.